Chemed (CHE) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Chemed Corporation  (NYSE: CHE)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare


Chemed's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Chemed's ROA in the second quarter of 2026?
Chemed Corporation achieved a return on average assets (ROA) of 17.58 % in its second quarter of 2026, this is above CHE's average return on assets of 15.65%.
Chemed Corporation assets over the 12 months ending in its second quarter of 2026 are valued at $1,564 million

ROA has improved compared to 16.25% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 58 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 319, from total ROA ranking in the first quarter of 2026 at 363.

What is ROA?



Return On Assets (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -8.05 % -12.23 % -0.97 % -0.92 % 7.11 %
Y / Y Net Income Change 28.98 % -7.6 % -15.02 % -15.23 % -25.95 %
Net Income (TTM) in million 275 260 265 279 290
Return On Assets (TTM) 17.58 % 16.25 % 16.06 % 16.84 % 17.5 %
CHE's Total Ranking # 319 # 363 # 309 # 297 # 277
Total Assets (TTM) in million 1,580 1,515 1,538 1,624 1,718
Seq. Total Assets Change 4.24 % -1.49 % -5.26 % -5.49 % -0.5 %
Seq. Net Income Change 2.11 % -13.61 % 19.48 % 22.37 % -26.85 %



Return On Assets Company Ranking
Within: No.
Industry # 0
Sector # 59
Overall # 277

Return On Assets Statistics
High Average Low
23.79 %
15.65 %
7.64 %
(Dec 31 2020)   (Jun 30 2017)





Financial Statements
Chemed's Assets $ 1,580 million CHE's Balance sheet
Chemed's Income $ 68 million Quarterly CHE's Income Statement
CHE's Income by Division See CHE's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change -0.41 % 0.03 % 17.91 % 7.38 % -7.17 %
Total Assets in million 1,538 1,544 1,544 1,310 1,220
Y / Y Net Income Change -12.17 % 10.82 % 9.17 % -7.05 % -15.94 %
Net Income in million 265 302 273 250 269
Annual Return On Assets 17.24 % 19.55 % 17.65 % 19.06 % 22.02 %




Comment on CHE's ROA in the fiscal year ending 2025
In the fiscal year 2025 Chemed's ROA decreased compared to previous year to 17.24 %, due to deterioration of net income -12.17 % to $265.24 million, from $302.00 million a year ago, as CHE's assets were $1,538.19 million.


More Return On Assets Ratios
CHE's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CHE's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CHE's Competitors
Subscribers only: Roa for Chemed's Suppliers
Subscribers only: Return On Assets for CHE's Customers

You may also want to know
CHE's Roi CHE's Inventory Turnover Ratio CHE's Growth Rates CHE's Dividend Comparisons
CHE's Profitability Ratios CHE's Asset Turnover Ratio CHE's Dividend Growth
CHE's Roe CHE's Valuation Ratios CHE's Financial Strength Ratios CHE's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %


Date modified: 2026-09-12T06:14:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.